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Cholesterol is a major constituent of the human brain, and the brain is the most cholesterol-rich organ. Numerous lipoprotein
receptors and apolipoproteins are expressed in the brain. Cholesterol is tightly regulated between the major brain cells and is
essential for normal brain development. The metabolism of brain cholesterol diﬀers markedly from that of other tissues. Brain
cholesterol is primarily derived by de novo synthesis and the blood brain barrier prevents the uptake of lipoprotein cholesterol
from the circulation. Defects in cholesterol metabolism lead to structural and functional central nervous system diseases such as
Smith-Lemli-Opitz syndrome, Niemann-Pick type C disease, and Alzheimer’s disease. These diseases aﬀect diﬀerent metabolic
pathways (cholesterol biosynthesis, lipid transport and lipoprotein assembly, apolipoproteins, lipoprotein receptors, and signaling
molecules). We review the metabolic pathways of cholesterol in the CNS and its cell-specific and microdomain-specific interaction
with other pathways such as the amyloid precursor protein and discuss potential treatment strategies as well as the eﬀects of the
widespread use of LDL cholesterol-lowering drugs on brain functions.
1. Introduction
Cholesterol is an important structural component of cellular
membranes and myelin and a precursor of oxysterols, steroid
hormones, and bile acids. Cholesterol is a major constituent
of the human brain (with about 35 grams of cholesterol in
an adult brain [1]), and the brain is the most cholesterol-
rich organ [2], containing about 20% of the body’s total
cholesterol. Brain lipids consist of glycerophospholipids,
sphingolipids, and cholesterol in roughly equimolar pro-
portions [3]. Cholesterol is tightly regulated between the
major brain cells—neurons and glia, that is, astrocytes,
microglia, and oligodendrocytes—and is essential for normal
brain development. Cholesterol is required for synapse
and dendrite formation [4, 5], and for axonal guidance
[6]. Cholesterol depletion leads to synaptic and dendritic
spine degeneration, failed neurotransmission, and decreased
synaptic plasticity [7]. Cholesterol is a pivotal constituent of
cell membranes, steroid hormones, and for the function of
the hedgehog protein [8]. Defects in cholesterol metabolism
lead to structural and functional central nervous system
(CNS) diseases such as Smith-Lemli-Opitz syndrome [9],
Niemann-Pick type C (NPC) disease [10], Huntington’s
disease [11], and Alzheimer’s disease [12]. These metabolic
defects aﬀect diﬀerent metabolic pathways such as (1)
cholesterol biosynthesis, (2) lipid transport and lipoprotein
assembly, (3) receptors that mediate the cellular uptake of
lipids, and (4) signaling molecules [13].
Unlike cholesterol in other organs in the periphery, brain
cholesterol is primarily derived by de novo synthesis. The
intact blood brain barrier (BBB) prevents the uptake of
lipoproteins from the circulation in vertebrates [14]. In cells
outside the brain, the need for cholesterol is covered by
uptake of lipoprotein cholesterol by cells as well as by de novo
synthesis [15]. The importance of this isolated cholesterol
pool in the CNS has been described as early as 1834 when
Couerbe called cholesterol “un element principal” (a key
element) of the CNS [16]. Cholesterol is synthesized via
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the isoprenoid biosynthetic pathway (for further details
see [17]). Isoprenoid biosynthesis starts with acetyl-CoA
as a substrate, which by means of 6 subsequent enzyme
reactions is converted into isopentenyl-pyrophosphate, the
basic C5 isoprene unit used for synthesis of all subsequent
isoprenoids. In total, at least 20 enzymes are involved
for the generation of cholesterol [17]. The 3-hydroxy-3-
methylglutaryl-coenzyme A reductase (Hmgcr; EC 2.3.3.10)
is the rate limiting enzyme in cholesterol biosynthesis and
the target of statin pharmacotherapy [18]. Besides choles-
terol, the cholesterologenic pathway forms other important
intermediates such as mevalonate, farnesyl pyrophosphate,
squalene, and lanosterol [19]. The first enzymes of the
isoprenoid/cholesterol biosynthetic pathway, that is, the
conversion of acetyl-CoA to farnesyl pyrophosphate, are
localized in the cytosol except for Hmgcr which, together
with most enzymes involved in cholesterol synthesis, is
localized in the endoplasmatic reticulum [20, 21].
In contrast to the distribution in plasma lipoproteins,
essentially all (>99.5%) cholesterol in the CNS is present in
an unesterified, free form [2]. There are two major pools of
CNS cholesterol: one pool (containing up to 70% of the CNS
cholesterol) consists of the myelin sheaths of oligodendrogl-
ia; the other pool is made up by plasma membranes of astro-
cytes and neurons. The lipid-protein composition of myelin
diﬀers from that of other cell membranes; myelin dry weight
consists of about 70% lipids and 30% proteins, in other
cell membranes the distribution is about 30% lipids and
about 70% proteins [2]. Major lipid constituents of myelin
are cholesterol, phospholipids, and glycosphingolipids in
molar ratios of about 4 : 4 : 2. The lipid composition, in
particular the cholesterol composition of myelin, is believed
to have a pivotal role inmembranemorphology and function
such as the transmission of nerve impulses. In neurons
(which are composed of cell body and axon), electrical
impulses are transmitted rapidly along the axon. The axon
is wrapped by myelin made up from the membranes of
several oligodendrocytes, separated by periodic gaps in the
myelin sheath—called nodes of Ranvier. This discontinuous
insulation allows the saltatory conduction of the action
potential. Due to its reduced permeability to ions, the
cholesterol enrichment of the myelin sheath propagates the
transmission of current along the axon rather than across the
membranes of oligodendrocytes [22].
2. Brain Cholesterol
Brain cholesterol is considered to be a distinct pool from
body cholesterol. Unlike cholesterol in other organs, there
is only minute exchange of cholesterol towards other organs
(2). The majority of brain cholesterol accumulates between
the perinatal period and adolescence when neurons are
encircled by specialized plasma membranes termed myelin.
After myelination, the metabolism of cholesterol in the
adult brain is characterized by a very low turnover and
minimal losses [23]. However, recent results indicate that
both cholesterol synthesis and degradation are active in the
adult brain as well and that alteration in these mechanisms
profoundly influences higher-order brain functions [24].
Several levels of evidence indicate a distinct metabolism
of CNS cholesterol. The brain does not respond to many
control mechanisms operative in maintaining cholesterol
homeostasis in the whole organism. The half-life of brain
cholesterol in the adult organism is between 6 months and 5
years [25, 26], the half-life of plasma cholesterol, in contrast,
is only a few days [27]. In the 1940s, administration of
deuterated water into rats led to an incorporation of the
label into the unsaponifiable lipids of the brain [28]. Similar
findings were observed in unrelated studies employing
deuterated cholesterol in dogs [29]. From the current level
of knowledge, in the CNS of mammals such as mice, rats,
and humans, >95% of cholesterol is synthesized de novo from
acetate and exchange between plasma lipoprotein cholesterol
and brain cholesterol has only very little impact [1, 30–33].
However, some studies could demonstrate the transfer of
small amounts of cholesterol from the periphery through
the BBB to the CNS. In humans, after administration of
4-14C-labelled cholesterol, on average 3.2% of the serum
label was detected in the CNS cholesterol [34]. A drawback
of this study is the fact that all patients were terminally
ill (most of them with malignancies) and a defective BBB
could not be excluded. No label was detected within the first
days after injection and the authors described the cholesterol
exchange as negligible. The accumulation ofminute amounts
of cholesterol was also observed in adult guinea pigs after
administration of hexadeuterium-labelled cholesterol with
an accumulation of 1.23% and 0.93% in the cerebrum and
cerebellum, respectively [35], and in mice and rats after
feeding a diet containing hexadeuterium-labelled cholesterol
with an accumulation of less than 1% [36].
Recent data indicate that besides being an important
constituent of the brain cell membranes, cholesterol as well as
the receptors for cholesterol-containingmolecules are pivotal
signaling molecules for brain morphology during embryonic
development. During embryonic development and in the
early postnatal period, the central nervous system undergoes
an enormous cellular expansion. A suﬃcient availability of
cholesterol as well as a correct ratio of cholesterol and phos-
pholipids is crucial for the physicochemical properties of cells
within the CNS. It is conceivable that during evolution a
checkpoint was established that determines which suﬃcient
cholesterol is available to proceed with the expansion of the
brain or whether cell division and growth are slowed down
[37]. The highest rate of cholesterol synthesis in humans
and rodents occurs during the first postnatal weeks [30, 38,
39]. This time window corresponds with the peak of the
myelination process and the myelination process is delayed
when cholesterol biosynthesis is deficient [40].
3. Sterol Flux between CNS Cells
A suﬃcient availability of cholesterol is necessary for normal
neuronal function and morphology, and both a lack and
surplus of cholesterol impair these features [41, 42]. Choles-
terol in neurons can be synthesized by neurons themselves
[43, 44] and can also be taken up from other cells within the
CNS, namely, from oligodendrocytes [45]. Oligodendrocytes
have a central role in cholesterol synthesis in the CNS.
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On the contrary, the role of neurons and glial cells in
cholesterol biosynthesis is still poorly understood [46]. Data
indicate that neurons (in particular regions of the brain
and/or under certain conditions) synthesize and take up
cholesterol from circumjacent oligodendrocytes. Enzymes
such as Hmgcr and 7-dehydrocholesterol reductase (Dhcr7;
EC 1.3.1.21) are expressed with high transcript levels in
cortical, cholinergic, and hippocampal neurons [47]. The
expression of cholesterol-synthesizing enzymes as well as
sterol-sensing factors, intracellular transporters, cholesterol
shuttle proteins, and lipoprotein receptors is diﬀerent within
regions of the brain [13, 48]. Consequently, diﬀerent regions
of the brain diﬀer markedly in their cholesterol content [49].
Duringmaturation of neurons, the endogenous synthesis
of cholesterol is impaired and the neurons depend on cho-
lesterol provided by astrocytes [50]. Brain-derived neu-
rotrophic factor (BDNF) is an important stimulus for de
novo synthesis of cholesterol in neurons [51]. The significant
transfer and uptake of oligodendrocytes-derived cholesterol
by neurons could be demonstrated by conditional ablation
of cholesterol synthesis in mice neurons. The conditional
gene inactivation of the squalene synthase gene (fdft1) in
neurons revealed a normal phenotype and function [45].
This supports the hypothesis that significant amounts of
cholesterol are transferred between diﬀerent cell types in the
CNS.
The transfer of cholesterol between diﬀerent cells is influ-
enced by the fluidity of cell membranes and the distribution
ofmicrodomains such as lipid rafts (also known as detergent-
resistant membrane fraction (DRM)). One example for
a disease with altered composition of cell membranes is
the deficiency of Dhcr7. Total or partial deficiency of
Dhcr7 causes Smith-Lemli-Opitz syndrome with the clinical
triad developmental deformities, incomplete myelination,
and mental retardation [52]. Tissue cholesterol and total
sterol levels are markedly reduced, and 7-dehydrocholesterol
levels are highly elevated [53]. High concentration of 7-
dehydrocholesterol inhibits Hmgcr which exacerbates the
cellular cholesterol deficit [54]. The altered membrane com-
position, in particular the increased 7-dehydrocholesterol
levels, increases membrane fluidity [55] and decreases the
intermolecular packing of phospholipid fatty acyl chains [56,
57]. The altered membrane composition leads to functional
changes. The depletion of cholesterol, followed by replace-
ment by 7-dehydrocholesterol in hippocampal membranes,
does not restore the ligand-binding of the serotonin 1A
receptor [58].
Abnormalities in cholesterol homeostasis have been also
observed in Huntington’s disease [59] and stress the necessity
of cholesterol transfer within cells of the CNS (i.e., between
the major site of cholesterol biosynthesis—oligodendroglia
cells—and neurons). Transcription of genes in the choles-
terol and fatty acid biosynthetic pathways are downregulated
in human postmortem Huntington’s disease striatal and
cortical tissues as well as in murine models of Huntington’s
disease [60]. The hallmark of Huntington’s disease, the
accumulation of mutant huntingtin protein within neurons,
is aﬀected by the ineﬃcient palmitoylation of huntingtin.
This palmitoylation is crucial for the normal function since
this process enhances the hydrophobicity of this protein
and determines the membrane association and the sub-
cellular traﬃcking between membrane domains [11, 61].
The accumulation of cytoplasmic and nuclear inclusions
leads to neuronal dysfunction and later to neuropathological
changes such as cell loss and atrophy in the putamen and
neostriatum.
4. Net Sterol Flux of CNS Cholesterol
Most of the CNS cholesterol is recycled. However, mecha-
nisms to export cholesterol into the circulation are manda-
tory to maintain homeostasis. Two diﬀerent pathways for
exporting cholesterol have been identified so far. Similar
to other cells such as macrophages, cells of the CNS,
in particular astrocytes, shed cholesterol associated with
apolipoprotein (apo) E into the cerebrospinal fluid (CSF).
Despite lipoproteins in the brain are secreted predominantly
by glia cells, neurons are also capable of synthesizing
lipoproteins under certain conditions [62, 63]. However, the
capacity of the shedding pathway is very limited and can
export only 1-2mg cholesterol per day [14]. The second,
quantitatively more important mechanism is the export of
cholesterol as 24(S)-hydroxycholesterol. Unlike nonoxydized
cholesterol, oxysterols such as 24(S)-hydroxycholesterol can
cross lipophilic membranes such as the BBB at a much
faster rate than cholesterol itself [64, 65]. The introduction
of a hydroxyl group into the side chain of cholesterol
leads to a local reordering of membrane phospholipids that
is energetically more favorable and allows a transfer of
oxidized cholesterol through the membrane several orders of
magnitude greater than that of nonoxidized cholesterol [66]
(Figure 1).
The flux of 24(S)-hydroxycholesterol through the BBB is
limited to about 6-7mg per day [64, 67].
In the circulation and in most tissues, cholesterol is
always present in a great excess compared to oxysterols with
the ratio of cholesterol to any oxysterol being 1.000 : 1 to
100.000 : 1 [68]. In the brain, however, the ratio is much
lower and varies between 500 : 1 and 1000 : 1 [67]. Oxys-
terols can shuttle between the membrane leaflets and can
be extracted by acceptors such as lipoproteins. Plasma
oxysterols are associated with membranes and in plasma
are bound to lipoproteins [69], similar to other lipids
present in trace amounts such as gangliosides [70, 71].
Similar to the ganglioside/cholesterol ratio [70], the ratio
of 24(S)-hydroxycholesterol to cholesterol in plasma is
rather constant and patients with hypercholesterolemia show
higher plasma concentration of 24(S)-hydroxycholesterol
[68].
While in the brain the oxidation of the steroid side chain
at position 24 is the primary mechanism for the elimination
of cholesterol, outside the brain the oxidation occurs at
position 27. The enzyme responsible for this reaction is sterol
27-hydroxylase (27-OHC, CYP27A1) and macrophages have
particularly high activities of CYP27A1 [68]. 27-hydroxycho-
lesterol is able to pass the BBB [65] and the daily influx of
27-hydroxycholesterol into the brain has been estimated to
be 5mg. This flux is dependent on the concentration in the
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Figure 1: Major cholesterol and apoE pathways in the CNS. Cholesterol is synthesized de novo in brain cells (neurons, astrocytes, microglial
cells). Eﬄux of CNS cholesterol through the BBB occurs as 24(S)-hydroxycholesterol (24S-OH-C) and 27-hydroxycholesterol (27-OH-C).
24S-OH-C is produced exclusively in the CNS, 27-OH-C is produced inmost organs. Unlike cholesterol, 24-S-OH-C and 27-OH-C can cross
the BBB because of the hydroxylated side chains. Primarily astrocytes and microglia secrete HDL-like lipoproteins composed of cholesterol
and phospholipids and apoE as the major apoprotein. ApoE is the ligand of these lipoproteins to the receptors of the LDL receptor family
such as the LDL-receptor and LRP. Exchange of cholesterol and apos between CNS cells occurs via these lipoproteins. In plasma, 24S-OH-C
and 27-OH-C are transported on lipoproteins such as LDL and HDL. De novo cholesterol synthesis in CNS cells can be regulated by the
apoE-mediated uptake of lipoproteins via the LDL receptor family. ApoE is produced within the CNS and interacts with Aβ. The availability
of cholesterol and of apoE are thought to aﬀect amyloidogenesis and apoE (in particular the isoform apoE4) promoting the formation of
amyloid fibrils from soluble Aβ in the CNS. The data for the steady state cholesterol pool have been determined from studies in healthy
adults. The flux of cholesterol across the whole body is ∼700mg/day (CHOL INPUT/OUTPUT). The flux across the CNS is only 0.9% of
whole body (∼12mg/day). The eﬄux of 24(S)-hydroxycholesterol through the BBB is limited to ∼6-7mg per day [64, 67], the daily influx
of 27-hydroxycholesterol into the brain has been estimated to be ∼5mg [1]. Please note that the brain per kg organ contains 10 times more
cholesterol than the rest of the body.
circulation and on the integrity of the BBB [72]. The rate
limiting step in bile acid synthesis is 7α-hydroxylation [73].
In the liver, 7α-hydroxylation of cholesterols is mediated by
CYP7A and CYP39A1 while in brain and other tissues, both
sterols and some steroids including dehydroepiandrosterone
are prominently 7α-hydroxylated by CYP7B [73]. In human
plasma, 7-hydroxycholesterol is the quantitatively most
prevailing oxysterol [69].
In the total organism, the pool of cholesterol is about
2200mg/kg body weight and similar in most species. How-
ever, the cholesterol pool in the CNS varies from about
330mg/kg body weight in the mouse up to 460mg/kg body
weight in primates [27]. In humans, the flux of cholesterol
across the whole body is about 10mg/day per kg body weight
while the flux across the CNS is 0.09mg/day per kg body
weight only [64] (Figure 1). In smaller animals such as the
mouse and the baboon, the rates are several folds higher. It
is remarkable that in all species studied so far, the percentage
of the rate of cholesterol flux across the CNS is about 0.09%
of the flux across the rest of the body [74, 75].
In humans, this eﬄux of 24(S)-hydroxycholesterol cor-
responds to the uptake of a similar amount of 24(S)-
hydroxycholesterol by the liver, which indicates the exclu-
sive production of 24(S)-hydroxycholesterol in the brain
[64]. CYP46, the cytochrome responsible for the 24S-
hydroxylation of cholesterol, is localized in neurons indi-
cating that neurons have a distinct role in the excretion of
cholesterol from the brain [76] and in the retina [77]. In
mice, 24S-hydroxylation of cholesterol also takes place in
the liver. However, 24S-hydroxylase knockout experiments in
mice revealed similar steady-state levels of cholesterol in the
knockout mice and in the wild-types. In contrast to the liver,
the synthesis of new cholesterol in the brain was reduced by
approximately 40% in knockout animals. These data suggest
that the synthesis of new cholesterol and the secretion of
24(S)-hydroxycholesterol are closely linked and that at least
40% of cholesterol turnover in the brain is dependent on the
action of cholesterol 24-hydroxylase [78].
Liver X-receptors (LXR) LXRα and LXRβ are important
regulators of cholesterol homeostasis in the body. LXRs are
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expressed in most tissues and organs and are activated by
a number of oxysterols, including 24(S)-hydroxycholesterol
[79–81]. LXRs regulate their target genes including ABCA1
and ABCG1, which mediate the eﬄux of phospholipids and
cholesterol from a number of cells including astrocytes [82],
and LXR agonists have marked eﬀects on gene expression
in murine brain in a cell-specific manner. LXR agonists
markedly enhance cholesterol eﬄux in astrocytes in culture
and have only a limited eﬀect on neuronal cultures [82]. The
binding of oxysterols to LXR in the presence of large excesses
of cholesterol has been questioned [83]. In the brain with a
much lower ratio of oxysterols to cholesterol [67] it was pos-
tulated that a net export of cholesterol is feedback-regulated
by LXRβ, ABCA1, CYP46, and 24(S)-hydroxycholesterol
[46]. LXR-dependent ABC transporters are also involved
in the influx of cholesterol from (perivascular) astrocytes
into the CNS [84]. Many other nuclear receptor (with
ligands such as fatty acids, oxysterols, and other lipids) are
also expressed in the brain. However, for most of them
we still have insuﬃcient knowledge on their role in brain
development and function [85]. Also apoE, the major apo
present in the CNS, is transcriptionally regulated by the
ligand-activated nuclear receptors, peroxisome proliferator-
activated receptor γ(PPARγ) and LXRs [86], which form
obligate heterodimers with retinoid X receptors. PPARγ:
retinoid X receptors and LXR: retinoid X receptors induce
the expression of apoE, its lipid transporters ABCA1 and
ABCG1, and the nuclear receptors itself [87].
5. Regulation of CNS Sterol Flux by
the Blood-Brain Barrier
The BBB formed by tight junctions between capillary
endothelial cells, separates circulating blood from the extra-
cellular fluid in CNS. The BBB is distinct from the blood-
cerebrospinal-fluid barrier, a function of the choroidal cells
of the choroid plexus.
The cells of the BBB have the potential to take up
low-density lipoprotein (LDL) cholesterol through luminal
endothelial receptors followed by a translocation across
the endothelial cell. This uptake, however, is not relevant
under physiological conditions and the lipoprotein receptor-
mediated uptake of cholesterol from the plasma does not
regulate brain cholesterol [88].
This finding is supported by the normal brain phenotype
of humans with LDL-receptor mutations that do not express
functional LDL-receptors [89]. Most of the studies, per-
formed on patients with pharmacological downregulation of
Hmgcr and overexpression of LDL receptors, showed no clear
eﬀect on brain cholesterol turnover [90–92] except for one
study with 18 study subjects that revealed a reduced brain
cholesterol turnover [93].
6. Cholesterol and the Signaling
Pathway of Hedgehog
Lipoprotein receptor (i.e., LRP2 [94]) knockout mice and
holoprosencephaly caused by defects in sonic hedgehog
(SHH) [95] have a very similar phenotype. Cholesterol has a
pivotal role in the signaling pathway of hedgehog. SHH par-
ticipates in signaling in vertebrates and avertebrates [95] and
is the best studied hedgehog homologue of the 3 mammalian
proteins sonic (SHH), desert (DHH), and indian (IHH).
SHH consists of a ∼45 kDa precursor protein and undergoes
autocatalytic processing to produce an ∼20 kDa N-terminal
signaling domain (referred to as SHH-N) and a ∼25 kDa
C-terminal domain with no known signaling function.
During cleavage, a cholesterol molecule is appended to the
carboxyl terminus. With cholesterol attached, SHH signals
in an autocrine fashion. Hedgehog signaling requires the
participation of dispatched protein. When SHH has reached
its target cell, it binds to the Patched (PTCH1) receptor.
In the absence of a ligand, PTCH1 inhibits smoothened
(SMO). SMO is regulated by a small molecule, the cellular
localization of which is controlled by PTCH. An anticancer
drug, vismodegib, has already been developed which inter-
feres with SMO and has the potential to inhibit constitutively
active SHH signaling pathways such as in medulloblastomas
[96]. PTCH1 has homology to Niemann-Pick disease type
C1 protein (NPCD1), a protein involved in the transport of
lipophilic molecules across membranes. PTCH1 has a sterol
sensing domain (SSD), which has been shown to be essential
for the suppression of SMO activity. PTCH1 regulates SMO
by removing oxysterols from SMO. For this regulation,
PTCH functions like a sterol pump and removes oxysterols
created by 7-dehydrocholesterol reductase. After binding to
SHH protein or to the SSD of PTCH, the pump is turned
oﬀ allowing the accumulation of oxysterols around SMO.
The interpretation of these findings is complicated by the
fact that mammals, unlike drosophila melanogaster, possess
more than one hedgehog (these are SHH, DHH, and IHH)
with tissue specific expression [97]. Recent data show that
SHH favors the integrity during maturation of the BBB, thus
providing a barrier-promoting eﬀect and an endogenous
anti-inflammatory balance to CNS-directed immune attacks
[98].
When embryonic development is studied inmicemodels,
the diﬀerences of the lipoprotein uptake between species has
to be accounted for as well as the maturation of the BBB
during embryonic development [99]. In embryonic develop-
ment, cholesterol derived in the maternal organism has to
cross the yolk sac endoderm to be available for the embryo. In
humans, fetuses rely on maternal cholesterol supply because
the endogenous synthesis is only low. Therefore, maternal
cholesterol can be crucial in fetal development [100]. The
contribution of maternal cholesterol to fetal cholesterol
homeostasis is more prominent in rodents [101] and appears
to be essential for early embryonic development in rodents,
as is also evident from the lethal fetal phenotype of mice
with defects in placental cholesterol transport [102]. Unlike
humans, in rodents apoB and microsomal transfer protein
[103] are essential for normal embryonic development. In
mice, partial or total apoB deficiency limits the uptake
of apoB-containing lipoproteins at the placenta and, as a
consequence, these mice suﬀer from apparent neural tube
defects [102]. Humans with apoB deficiency do not suﬀer
from neural tube defects [8].
6 Cholesterol
7. Cholesterol Synthesis Inhibitors
Cholesterol synthesis inhibitors (CSIs) (also known as
statins) are widely administered for reducing LDL cholesterol
[104]. Themain eﬀect is the inhibition ofHmgcr but an array
of pleiotropic eﬀects of statin therapy has been observed
[18, 105, 106]. Given the widespread use of statins, it is of
particular interest whether CSI aﬀect the metabolism of CNS
cholesterol or not and whether an eﬀect of (certain) CSI
has any clinical impact on the CNS morphology or on neu-
rological function [107–110]. Retrospective cohort studies
have suggested that statin users have a lower prevalence of
dementia. On the other hand, a randomized controlled study
failed to show beneficial eﬀects on the cognitive decline in
AD [111].
This topic is rather complex due to several open issues.
First, the CSIs used for the treatment of hypercholesterolemia
(such as simvastatin, lovastatin, atorvastatin, fluvastatin,
pravastatin, rosuvastatin, and pitavastatin) diﬀer in their
lipophilicity. A higher hydrophilicity/lower lipophilicity of a
pharmaceutical compound and its active metabolites will, in
the absence of specific transporters, lead to only very low
concentrations within the CNS. Second, the very eﬃcient
mode of action of these substances, namely, the induced
overexpression of LDL receptors, is not eﬀective in the CNS
since these receptors are not expressed within the CNS [89,
112]. Third, studies such as the 24S-hydroxylase knockout
experiments in mice [78] indicate a very tight, unique,
and independent regulation of cholesterol synthesis and
eﬄux within and from the CNS. Finally, other eﬀects of
CSI—described as pleiotropic eﬀects—such as eﬀects on
vascular injury, on cytokine production, and on nitric oxide
production [18] might influence the integrity of the BBB
[113] and any eﬀects observed on cholesterol metabolism
might be only indirect. In fact, it has been shown that
simvastatin may reduce posttraumatic edema by preventing
damage to tight junctions and neutrophil infiltration into the
parenchyma, thus preserving BBB integrity [114].
Diﬀerences in BBB permeability coeﬃcients might be a
clue to the higher incidence of neurological adverse events
of some statins. BBB permeability was studied using bovine
brain microvessels or by analyzing brain extracts of statin-
fed rats. Lovastatin and simvastatin had much higher BBB
permeability coeﬃcients than did fluvastatin, pravastatin, or
rosuvastatin [115–117]. The results with atorvastatin and
cerivastatin (the latter not available in the market anymore)
are ambiguous. Some researchers report high BBB perme-
ability coeﬃcients for atorvastatin [118], others for cerivas-
tatin [119]. Transfer of the lipophilic compounds lovastatin
and simvastatin across the BBB occurs via passive diﬀusion,
whereas pravastatin is taken up by an active, low aﬃnity
system [120]. The negative charge of fluvastatin aﬀects
the uptake by repulsion from the anionic microdomains
in the plasma membrane of BBB endothelial cells [115].
Interesting results were obtained in the short-term treatment
comparing the lipophilic simvastatin with the hydrophilic
pravastatin in mice. Brain cholesterol synthesis in mice
is significantly aﬀected by simvastatin while whole-brain
cholesterol turnover is not disturbed. Pravastatin can cross
the BBB but does not aﬀect intracellular cholesterol synthesis
[107].
In a mechanistic approach, the eﬀects of CSI on brain
cholesterol could occur by forming a cholesterol gradient
across the BBB which facilitates the eﬄux of cholesterol
as 24(S)-hydroxycholesterol [121]. However, current knowl-
edge is not suﬃcient to quantify the eﬀect of CSI treat-
ment on brain cholesterol. High doses (80mg per day) of
simvastatin did reduce the synthesis of CNS cholesterol in
vivo (as analyzed by the eﬄux of 24(S)-hydroxycholesterol)
[93] and the highly lipophilic lovastatin inhibited cholesterol
synthesis and synaptogenesis in vitro [122]. The analysis of
the ratio of plasma 24(S)-hydroxycholesterol to cholesterol
after treatment of patients with high doses of CSI, however,
revealed a decreased ratio and it was postulated that this was
caused by a diminished substrate supply for CYP46A1 in the
brain [93]. Conflicting data have been obtained from the
treatment of patients with NPC disease. In NPC disease—
a lysosomal lipidosis due to defective lipid transport [10]—
the accumulation of tissue lipids in neuronal cells such as
Purkinje cells cannot be treated by aggressive cholesterol
lowering pharmaceutical approaches, neither in humans
[123] nor in a mouse model [124], despite CSI therapy
lowered whole body cholesterol very eﬃciently. When NPC
disease was treated with allopregnanolone, a strong benefit
was observed but it could have come solely from the vector,
cyclodextrin. Cyclodextrin, a cyclical oligosaccharid with a
hydrophilic exterior and a lipophilic interior is an ideal
chelator for sterols and is the most eﬀective treatment option
for NPC disease in the mouse model [10].
Cholesterol is vital to normal brain functions including
learning and memory but that involvement is as com-
plex as cholesterol synthesis, metabolism, and excretion.
Dietary cholesterol influences learning tasks in mice and
rats in diﬀerent experiments such as water maze and fear
conditioning even though cholesterol does not cross the
BBB [125, 126]. Excess cholesterol in the brain can lead
to many signaling events via cholesterol metabolites, pro-
inflammatory mediators, and antioxidant processes [126].
Correlations of cholesterol levels with cognitive function
have been found to be positive, negative, or to have no
relationship at all. An important confounder is patient age.
High plasma cholesterol had detrimental eﬀects in middle-
aged persons [127–131] but had positive eﬀects in the very
elderly [132] and no eﬀects in the young [133]. Cholesterol
reduction by statin therapy improves memory in some cases
but not others. Numerous reports as well as small trials have
suggested that statin therapy causes cognitive impairment,
although the true extent of this eﬀect remains under study.
The postmarketing adverse event reports generally described
individuals over the age of 50 years who experienced
notable but ill-defined memory loss or impairment that was
reversible upon discontinuation of statin therapy. Time to
onset of the event was highly variable, ranging from one
day to years after statin exposure [105]. Muldoon et al.
[134] observed minor decrements in cognitive functioning
with statins. On the other end, treatment with lovastatin
or pravastatin did not cause any psychological distress or
substantially alter cognitive function [135, 136]. Data from
Cholesterol 7
the observational studies and clinical trials did not suggest
that cognitive changes associated with statin use are common
or that statin use leads to clinically significant cognitive
decline. In any case, the FDA has recently updated the
recommendation for statins in order to reduce the risk of
cognitive adverse eﬀects and to provide the public with more
information about the safe and eﬀective use of statins [137].
Although epidemiology and preclinical statin research have
generally supported an adverse role of high cholesterol levels
regarding Alzheimer’s disease (AD), human studies of statins
show highly variable outcomes, making it diﬃcult to draw
firm conclusions [105].
The diﬀerence in the lipophilicity of diﬀerent statins
studied was not suited to explain their fitness for use in the
statin treatment of dementia or AD [138–140]. However,
of particular interest are drug-specific eﬀects obtained in
gene expression studies when comparing diﬀerent CSI [141].
Interesting results were also observed when studying the
eﬀects of statins in the presence and absence of mevalonate.
Despite cholesterol synthesis was blocked by the inhibition
of Hmgcr, as expected, the isoprenylation continued unim-
peded [142]. From the current knowledge, the diﬀering
eﬀects of diﬀerent statins on brain functions might be
modulated by their eﬀects on metabolic pathways other than
the cholesterol pathway.
Hypercholesteremia can induce τ-hyperphosphorylation
and Aβ production in rat brain. Atorvastatin inhibited τ-
hyperphosphorylation and decreased Aβ generation, thus
playing a protective role in the pathogenesis of hypercho-
lesteremia-induced neurodegeneration in the brain [143]. In
mice, early treatment with both atorvastatin and pitavastatin
prevented subsequent worsening of cognitive function and
the amyloidogenic process, probably due to pleiotropic
eﬀects, suggesting a therapeutic potential for AD patients
[144]. In AD patients, simvastatin treatment caused amodest
but significant inhibition of brain cholesterol biosynthesis,
as measured by a decrease of cerebrospinal fluid lathosterol
and plasma 24(S)-hydroxycholesterol. Despite these eﬀects,
there were no changes in AD biomarkers [145]. In another
study, atorvastatin was not associated with significant clinical
benefit [146]. One possible interpretation might be that
statins prevent or delay the onset of AD, but cannot slow the
cognitive decline once the disease process has started.
Higher levels of isoprenoids favor APP-processing by α-
secretase and less amyloid β (Aβ) is being secreted. Low
concentrations of isoprenoids inhibit the metabolism of APP
through the secretory pathway and lead to the intracellular
accumulation of Aβ. Low intracellular cholesterol levels
inhibit receptor-mediated endocytosis of APP. In mice, the
inhibition of protein isoprenylation by fluvastatin, at a
clinically relevant dose, reduced brain Aβ levels by increasing
the traﬃcking of APP carboxyl terminal fragments and
by enhancing Aβ clearance mediated by upregulation of
low-density lipoprotein receptor-related protein 1 (LRP-1)
expression [147].
Other protective eﬀects of statins besides their plasma
cholesterol lowering without alteration of the isoprenoid
levels [142] were obtained in studies with stroke patients
and in prospective studies. In observational studies, patients
under CSI treatment had lower likelihoods of mortality as
well as of poor functional outcome [148] and the discontin-
uation of CSI after ischemic stroke has been associated with
worse outcomes [149]. Studies with very high doses (up to
8mg/kg body weight) of lovastatin are under way and have
indicated an acceptable safety profile [150]. The use of CSI,
however, has been shown to increase the risk of bleeding after
ischemic stroke, irrespective of plasma cholesterol concen-
tration. Studies show no clear positive eﬀects for CSI on
cerebral hemorrhage, although atorvastatin has been shown
to significantly relieve brain edema, to decrease the brain
injury caused by matrix metalloproteinase-9, and to protect
neurons in rats with intracerebral hemorrhage [151].
Other important confounding factors of the human
epidemiological studies performed so far are the stage of
Alzheimer’s disease in the patients studied, the drug dose, the
duration of therapy and the adherence to the prescribed
drug, and the overlap of Alzheimer’s disease with other forms
of dementia and vascular disease [105]. While in vitro eﬀects
are fairly well understood, the results from in vivo studies
in humans are conflicting and additional research work is
urgently needed with highly standardized study designs to
address the impact of CSI on brain cholesterol metabolism
and Alzheimer’s disease. Currently, routine use of CSI in CNS
disease cannot be recommended except for lowering LDL
cholesterol in cerebrovascular disease [106].
8. Cerebrospinal Fluid Lipoproteins
Essentially all cholesterol within the CNS is associated with
cell membranes and only tiny amounts are located within
the intercellular space and in the CSF under physiological
conditions. Cholesterol within the intercellular space and in
the CSF is associated with apos, in particular with apoE. A
very high expression of apoE was observed during regener-
ation of peripheral nerves after damage [152] and apoE—
associated with lipids—was the most abundant protein in
the intracellular fluid. ApoE is also expressed within the
CNS and astrocytes secrete lipoprotein particles composed
of apoE, apoAI, and lipids (Figure 1). ApoE in the CNS has a
higher apparent molecular weight due to a higher sialylation
and is exclusively lipid-bound [14, 153]. The role of apoE-
containing lipoproteins is postulated to redistribute lipids
and to regulate cholesterol homeostasis within the brain.
The concentration of lipoproteins in the CSF is low.
Compared to plasma, in CSF the concentration of apoE is
about 5%, of cholesterol about 1%, and of phospholipids
about 2% only. Triglycerides are present in trace amounts
and apoB is absent. The concentration of lipids in the CSF
does not correlate with the plasma lipid concentration [154].
CSF lipoproteins are bigger in size than plasma HDL and
smaller than LDL, their density is between LDL and HDL
[14]. Their composition with esterified cholesterol as core
lipid, their size, and density is very similar to lipopro-
teins secreted from macrophages [155] or from transfected
neuro2a cells [156]. However, nascent apoE/lipid particles
secreted by cultured astrocytes are primarily discoid and
contain only small amounts of lipids such as cholesterol and
phospholipids [157]. Besides small amounts of apoA-I, CSF
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lipoproteins contain trace amounts of apoA-II, apoC-I, and
apoC-III. These small, lipophilic apos are derived from the
plasma and have leaked through the blood brain barrier.
ApoE and apoB cannot cross the BBB [158], however, in case
of a BBB breakdown, plasma components can spill into the
CSF and apoB can be detected in the CSF.
9. LDL Receptor Family in the CNS
Numerous lipoprotein receptors of the LDL receptor family
have been detected in the CNS by biochemical and molecu-
lar methods (LDL receptor, VLDL-receptor, apoER2/LRP8,
LRP4, LRP, LRP2 (formerly known as gp330 or megalin),
LRP1B, LRP5/LRP6, and LRP11/SORL1) [13, 159]. Ligands
for these receptors are apoE-containing lipoproteins, lipids
and other macromolecules [14, 153, 160]. However, the
spatial expression in diﬀerent cells such as neurons, astro-
cytes and microglia—even diﬀerent for cell lines within
diﬀerent regions of the brain—and the diﬀerent temporal
expression with a particular high expression postnatally
suggest important functions during embryogenesis and for
the functioning of the CNS. In fact, these multifunctional
and evolutionary ancient receptors have been shown to be
intercellular signal transducers and signal modulators [13].
The diﬀerential roles of these receptors in the CNS
are impeded by their redundant functions, similar or even
identical specificity for certain ligands, and the coexpression
in certain organs or even in one cell. Transgenic animal mod-
els are of very limited use because of relevant interspecies
diﬀerences in particular in regard of structural diﬀerences
of the placenta and the necessity of certain lipoproteins
and lipoprotein receptors for the lipid transfer from the
maternal organism during embryogenesis. The requirement
for the same receptor at two stages of lipid transport into
the embryo makes it diﬃcult to unequivocally determine the
participation of these molecules at a certain step, that is, on
the yolk sac surface or at the neuroepithelium [37].
The study of the evolutionary highly conserved sig-
naling pathways by mouse genetics revealed critical func-
tions for the receptors of the apoE-receptor family. Both
knockout mice lacking LRP2 [161] and double knockout
mice lacking both apoER2/LRP8 and the VLDL-receptor
[162] show severe defects in brain development. The latter
are phenotypically indistinguishable from mice lacking the
signaling protein Reelin and from mice with mutations in
the cytoplasmic adapter protein Disabled-1 (Dab1) [163].
This phenotype suggested that apoER2/LRP8, as well as
the VLDL-receptor, functions in a linear signaling pathway
that is dependent on the extracellular ligand Reelin and the
intracellular adaptor Dab1 for initiating a signaling cascade
that regulates the migration and positioning of neurons dur-
ing development [163]. Further studies revealed a signaling
through the Src family tyrosine kinase through proximity
triggered phosphorylation [164]. Other signaling pathways
are also active in microglia and neurons as indicated by the
interaction of the ATP-binding cassette transporter ABCA1
(the member 1 of human transporter subfamily ABCA), also
known as cholesterol eﬄux regulatory protein (CERP), with
the MAP-kinase-system [165].
The novel downstream interactions are partly dependent
upon unique interaction motifs within the cytoplasmic
domain of the receptors which helps to explain the specific
and nonredundant roles of ER2/LRP8 and VLDL-receptor
in shaping brain regions in response to binding of the same
ligand. For instance, the specific topography of the Purkinje
cell layer is regulated by the ER2/LRP8 and the VLDL-
receptor and in the neocortex [166], the VLDL-receptor pro-
vides a stop signal formigrating neurons while apoER2/LRP8
regulates the migration of later-borne neurons essential for
the proper lamination of neocortex and hippocampus [162].
In the peripheral neurons, LRP4 is essential for the function
of the neuromuscular junction. LRP4-deficient mice are
stillborn. LRP4 is an obligate coreceptor for the muscle
specific tyrosine kinase MUSK and the neuronally produced
ligand agrin. Only in the presence of LRP4, agrin leads
to clustering and transphosphorylation of MUSK. In the
absence of LRP4, MUSK transphosphorylation cannot occur
and acetylcholine receptors fail to form postsynaptic clusters
[167].
Despite all genes of the LDL receptor family have been
disrupted in the mouse, human mutations besides the LDL
receptor have been identified so far only in LRP2 and in
the VLDL receptor. Defects in LRP2 cause Donnai-Barrrow
syndrome, congenital agenesis of the corpus callosum,
diaphragmatic hernia, facial dysmorphology, ocular anoma-
lies, sensorineural hearing loss, and development delay [168].
The defects in patients are similar but not identical to
those seen in LRP2 knockout C57bl/6X129 hybrid mice
[168].This indicates genetic modifiers among species and
even within diﬀerent mice strains. VLDL-receptor deficiency,
a fully autosomal recessive trait, leads to a similar but
more severe phenotype in humans compared to mice [169].
In humans, distinct mutations have been observed in the
Canadian Hutterite population [170] and in Middle Eastern
populations [171]. Neuroanatomically, these mutations are
indistinguishable but considerable variations exist in regard
of motor development. Several, but not all, aﬀected individu-
als are quadrupedal and it has been suggested that the VLDL
receptor is the critical gene for the evolution of the bipedal
gait [171]. Other human autosomal recessive diseases with
virtually identical phenotypes to VLDL receptor deficiency
are caused by mutations of chromosome 17 [172]. Crk, a
downstream component of the Reelin signaling pathway, is
located in this chromosome region [169].
10. Apolipoproteins (apoE and apoJ) within
the CNS
The pivotal role of apoE for cholesterol recycling in the
regenerating peripheral nerve has been long recognized
[173]. ApoE, a 39 kD protein, is the major apo in the
CNS. Three major alleles of Apoe (ε2, ε3, ε4) are expressed
codominantly and lead to common phenotypes E22, E23,
E24, E33, E34, and E44. ε3 is the most common allele (about
77%) and ε2 is the least common (about 8%) of these
major alleles [174]. ApoE2 has a defective binding to the
LDL-receptor and is responsible for type III hyperlipidemia.
ApoE3 as well as apoE4 are high aﬃnity ligands for
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the LDL-receptor [175]. ApoE consists of two domains (the
N- and C-terminal domains) separated by a protease-
sensitive hinge region. The diﬀerences between apoE iso-
forms are arginine-to-cysteine changes in the N-terminal
domain. ApoE4 contains arginines at positions 112 and 158,
whereas apoE3 has a Cys112 [175].
The functions of apoE in the CNS are heterogeneous and
range from participation in cholesterol homeostasis and in
nonlipid activities such as protein chaperoning and signal
transduction [176]. ApoE is expressed in the brain in
high concentrations, such that the brain is the organ with
the second highest apoE expression after the liver [177].
Astrocytes are the major source of apoE followed by
oligodendrocytes, microglia, and ependymal layer cells [178].
The significance of apoE expression in neurons has not
been resolved yet. Some CNS neurons may express apoE
under certain condition such as after excitotoxic injury [179]
and apoE expression was observed in primary cultures of
human hippocampal neurons and in mice expressing human
apoE under the control of the human apoE promoter [176].
The stability of apoE in the brain requires the association
with lipids. In knockout mice for Abca1—a gene necessary
for the lipidation of apoE—the amount of apoE in the
brain is reduced [180, 181]. The LDL-receptor and LRP1
are the main receptors for the uptake of apoE containing
lipoprotein particles in the brain. LDL-receptor knockout
mice have increased levels of apoE in brain parenchyma
and in CSF [182] which suggests impaired metabolism
of apoE. A conditional deletion of Lrp1 gene in mouse
brain decreases brain parenchyma apoE [182]. ApoE is the
major apo of CSF lipoproteins [14, 157, 158]. Similar to
lipoprotein cholesterol, apoE does not cross the BBB. This
was demonstrated by the analysis of apoE phenotypes after
liver transplantation when no donor apoE can be found in
the CSF of the recipient [177].Whether apoE has amajor role
in supporting synaptogenesis and maintenance of synaptic
connections in vivo in the uninjured brain is unclear. In
apoE knockout mice, brain morphology and behavior are
not altered in the absence of injury [183, 184] and no overt
cognitive defects have been reported in humans with genetic
apoE deficiency [185]. It has been suggested that there is a
dynamic exchange of apoE among brain cells, that apoE is
the major transport protein for extracellular cholesterol and
other lipids, and that apoE-mediated cholesterol exchange
occurs between neuronal and nonneuronal cells of the CNS
[176].
Several lines of evidence link apoE with late-onset Alz-
heimer’s disease, the most common cause of dementia in
the elderly. Epidemiological studies highlighted the ε4 allele
of Apoe as the most common risk factor for late-onset
Alzheimer’s disease [186], and in vitro studies showed a
colocalization of apoE with amyloid plaques [187] and a
positive correlation between plaque density and number of
ε4 alleles in Alzheimer’ patients at autopsy [188].
ApoE is a risk factor with relatively low penetrance but
with high prevalence [189]. Individuals with one ε4 allele
are 3 to 4 times more likely than those without ε4 alleles to
develop late-onset Alzheimer’s disease [189] and suﬀer from
Alzheimer’s disease at a younger age [190]. Individuals with
the ε2 allele have a lower risk of late-onset Alzheimer’s disease
compared to the ε3 allele ([186], for results of meta-analyses
see http://www.alzgene.org/). However, most homozygotes
for ε4 will not suﬀer from Alzheimer’s disease and most
patients with Alzheimer’s disease are not homozygous for ε4
[189].
The search for the molecular mechanisms of apoE4 pro-
moting Alzheimer’s disease is still ongoing despite 20 years
of intense research. These molecular mechanisms would
be attractive pharmaceutical targets for the prevention and
treatment of Alzheimer’s disease [176]. One hypothesis pro-
poses a “toxic” mechanism of apoE4, the other hypothesis is
a failure of apoE4 to slow down the disease process as
eﬀectively as apoE3 and apoE2 do. These hypotheses have
direct implications in devising therapeutic strategies. In the
first hypothesis, the treatment would have to block apoE4, in
the second hypothesis the treatment has to potentiate or to
mimic apoE3 [191].
Biochemical studies elucidated isoform-specific diﬀer-
ences between diﬀerent apoE isoforms, in particular between
apoE3 and apoE4. The design of these studies is hindered by
the lack of apoE isoforms in animals. Diﬀerent apoE isoforms
are only present in humans; all animal apoEs studied so
far contain Thr at the equivalence to the position Arg61 in
human apoE4. Therefore, irrespective of the amino acid at
position 112, animal apoE behaves like human apoE3 [192].
ApoE4 binds to large lipoprotein particles, attributable
to the presence of Arg112, which aﬀects the conformation of
the side chain of Arg61 in the N-terminal domain resulting
in domain interaction between Arg61 and Glu255 in the
C-terminal domain [193]. Unlike apoE3, apoE4 is assumed
to produce an unstable “molten globule” state that is
responsible for the pathogenic role in Alzheimer’s disease
[194]. Molten globule domains interact with diﬀerent target
molecules, typically with high-aﬃnity and low specificity
[195]. Since the isoform-specific diﬀerences between apoE3
and apoE4 are outside the receptor-binding region, studies
have evaluated the molecular interaction of apoE with
proteins present in the neuritic plaque. Lipid-bound (i.e.,
physiologic) as well as artificially delipidated apoE forms
complexes with Aβ. However, the order of stability of the
complexes dependent on apoE isoform was not uniform
[196, 197]. Data from in vitro studies indicate that apoE
enhances cellular Aβ uptake and degradation [196, 198, 199]
but in vivo studies revealed that apoE retards Aβ clearance
[200, 201], possibly via an eﬀect at the BBB [202]. Until
now, the whole wild type apoE could not be crystallized
and all crystallographic studies could only be performed on
fragments of the protein or after site directed mutagenesis
[203]. Another challenge results from self-aggregation of
the protein and from the formation of oligomers. When
lipids are added to the delipidated protein, the protein
undergoes large structural changes [204], and it is not clear
whether diﬀerences observed with the delipidated protein
are retained after lipidation [203]. The structure of the
N-terminal domain (i.e., the receptor binding domain) of
apoE3 and apoE4 has been determined using both X-ray
and NMR methods [205, 206]. The isolated C-terminal
domain—responsible for lipid binding, for oligomerization
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and probably for Aβ binding—is known to aggregate which
prevents structure determination by standard methods
[192]. Studies performed with transgenic animals only
expressing apoE 3 or apoE4 either in neurons or in astrocytes
showed a detrimental eﬀect of apoE4 on all subunits of
mitochondrial respiratory complexes assessed and treatment
of these cells with a compound disrupting apoE4 domain
interaction restored mitochondrial respiratory complex IV
levels. Mutant apoE4 (apoE4-Thr-61) lacking domain inter-
action did not induce mitochondrial dysfunction [207].
Recently, results of the first pharmacological interven-
tions with apoE as target performed in mice have been
reported. One study has targeted at the apoE isoform-specific
eﬀects on the BBB. In the absence of murine apoE, human
apoE4 but not apoE3 or apoE2 leads to BBB breakdown by
activating the proinflammatory cyclophilin A in pericytes
[208]. Another study overexpressed (murine) apoE in the
brain by the oral application of the FDA-approved RXR ago-
nist bexarotene. This study demonstrated a beneficial eﬀect
of CNS apoE overexpression [209], and it was concluded
that apoE overexpression might be able to decrease the pro-
gression of Aβ deposition. The proposedmechanism consists
in the absorption of Aβ by the CNS-derived lipoproteins
followed by the clearance of these particles from the brain.
However, only murine apoE was tested and no apoE isoform-
specific eﬀects have been reported so far [191]. Another
study employed an apoE-mimetic peptide called ApoE-
(133-149) which was administered intraperitoneally, has
optimized BBB penetration, and showed neuroprotection
[210]. Previous studies with this peptide in mice with
targeted replacement of apoE indicate human apoE isoform-
specific eﬀects on immune reactions with an increase in
proinflammatory cytokines in apoE4-expressing mice [211].
Unlike native apoE, ApoE-(133-149) lacks the lipid binding
region and will not be exclusively lipid-bound. Besides
its immunomodulatory eﬀects on microglia in the CNS
and macrophages outside the CNS, the peptide may aﬀect
cholesterol metabolism as well as LRP expression and LRP
receptor binding [211].
Apolipoprotein J (also known as clusterin) is also present
in lipoprotein particles and regulates cholesterol and brain
lipid metabolism [212]. Similar to apoE, the expression of
clusterin in the brain changes significantly during develop-
ment [213] and during diﬀerent kinds of neuronal injuries
[214] and increases in Alzheimer’s disease [212]. Clusterin
is a versatile chaperone molecule which contains several
amphipathic and coiled-coil alpha-helices, typical character-
istics of small heat shock proteins. Clusterin was originally
identified in Sertoli cells but very early, the high expression
of clusterin in the brain [215] and its role in cholesterol
traﬃcking has been established [212]. The secondary struc-
ture of clusterin contains molten globule domains [216]. Of
particular interest is the role of clusterin in the clearance
of Aβ peptides. Secreted Aβ peptides bind avidly to apoE
and to clusterin/apoJ, which prevents the oligomerization
of these Aβ peptides. A minor part of this complex is
endocytosed by microglia and astrocytes and degraded by
insulin degrading enzyme and neprilysin but the major part
is endocytosed without degradation. The major receptors for
the uptake at the blood-brain barrier are LRP and LRP2 [94,
217]. The third clearance pathway, besides the proteolytic
degradation and the endocytic uptake by microglia and
astrocytes, is the eﬄux of Aβ peptides through the blood-
brain barrier. This eﬄux is mediated by LRP1 [218] and by
LRP2 [219]. A downregulation of LRP1 is correlated with
regional Aβ accumulation in Alzheimer’s disease [218]. For
the clearance of Aβ in the brain, apoE and clusterin/apoJ have
a comparable and interchangeable function.
In summary, the function of the apoE receptors in
neurons is distinct but with similar molecular mechanisms,
in particular in intra- and intercellular signaling. These
receptors are critical for the formation and the function of
central and of peripheral synapses. Cholesterol and apoE
play a particular role as constituents of the ligands to these
receptors.
11. Amyloid Precursor Protein and Cholesterol
The accumulation, oligomerization, and deposition of Aβ
(a cleavage product of amyloid precursor protein APP) are
hallmark of Alzheimer’s pathogenesis. Aβ is a intrinsically
disordered protein, which can self-aggregate and form an
array of supramolecular assemblies with diﬀerent morphol-
ogy including oligomers, amorphous aggregates, and amy-
loid like fibrils. Cholesterol is involved in several steps of
Aβ processing. The elimination products, the oxysterols such
as the brain-specific 24(S)-hydroxycholesterol, as well as 27-
hydroxycholesterol increase sAPP production and contribute
to amyloidogenesis [220] with 24(S)-hydroxycholesterol
having more pronounced eﬀects than 27-hydroxycholesterol
[81]. Plasma 27-hydroxycholesterol concentration was asso-
ciated with CSF sAPP levels [221].
The selective expression of CYP46A1 around neuritic
plaques and the potent inhibition of APP processing in
neurons by 24(S)-hydroxycholesterol suggest that CYP46A1
aﬀects the pathophysiology of Alzheimer’s disease [81]. ApoE
and its receptors are closely involved in these processes.
ApoE as well as LRP1 are present in amyloid plaques [187]
and apoE regulates isoform-specifically APP processing to
Aβ by mechanisms dependent on LRP1 function. ApoE4
increases Aβ production in neuronal cells overexpressing
APP to a greater extent than apoE3. After incubation with the
LRP1 receptor antagonist RAP or by RNA interference, this
isoform-specific eﬀect was blunted [222]. Three other apoE
receptors (LRP1B, APOER2, LRP11/SORL1) also interact
with APP and regulate its traﬃcking and processing to Aβ
[223]. All these receptors reduce Aβ processing due to their
slow rate of endocytosis. In the absence of common ligands,
however, APOER2 increases the distribution of APP into
special cholesterol-rich membrane subdomains (also known
as detergent-resistant membrane fraction (DRM) or lipid
rafts) and the processing of APP to Aβ [224]. DRMs are
abundant on the cell surface and are enriched in cholesterol
and sphingolipids and a variety of proteins. Sorting signals
that target proteins to DRMs include binding to cholesterol,
sphingolipids and GPI-anchors, and other lipid modifica-
tions such as palmitoylation and myristoylation [3]. Lipid-
lipid interactions are one of the major mechanisms to form
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DRMs. DRMs are thought to represent liquid-ordered (LO)
domains, which coexist in the same membrane together
with liquid-disordered (Ld) domains [3]. LO domains are
formed due to the preferential interaction of sphingolipids
and/or phospholipids containing saturated acyl chains with
cholesterol [225]. Cholesterol has been shown to be a
critical regulator of DRM formation and the local regulation
of cholesterol levels by cholesterol biosynthesis, compart-
mentalization and secretion of cholesterol is a powerful
mechanism to control DRM-dependent events.
Aβ is cleared from the brain by two pathways. First,
through receptor-mediated endocytosis by cells in brain
parenchyma and along the interstitial fluid or through the
BBB and second, through endopeptidase-mediated prote-
olytic degradation. The receptor-mediated endocytosis by
members of the LDL-receptor family on astrocytes [226]
and microglia [227] can be an eﬃcient way to reduce brain
Aβ. Most Aβ internalized by apoE receptors is degraded
in lysosomes or is transcytosed into the plasma. However,
Aβ can escape from degradation or transcytosis, accumu-
lates in neurons, and exerts its toxicity on the neuronal
function [228]. Opposite to murine studies in which apoE
overexpression decreased Aβ deposition [208–210], in mice
overexpressing Aβ under control of the PDGF promoter, the
lack of apoE markedly diminished Aβ deposition [229].
Aβ generation is localized in DRMs or rafts. The enzyme
responsible for the enzymatic cleavage of APP called β-
secretase, or β-site APP cleaving enzyme (BACE), is found
in DRMs in primary hippocampal neurons [230]. The other
proteins necessary for the processing of APP have been
located in the DRMs of the late Golgi and endosomes,
the organelles where BACE is thought to be biologically
activated. The complete Aβ generating proteolyticmachinery
colocalizes within DRMs of the same vesicle [231]. A clue to
the complex APP processing comes from studying the eﬀects
of diﬀerent cholesterol concentrations [230]. In cells being
cholesterol-depleted and overexpressing APP, further lower-
ing of cholesterol inhibits amyloidogenesis [91, 232, 233].
In neurons with normal cholesterol content, a moderate
reduction of cholesterol led to increased Aβ levels whereas
a strong cholesterol reduction resulted in a significant drop
in Aβ generation. These cholesterol dose-dependent eﬀects
can be explained by two independent cellular mechanisms
[231]. First, a moderate reduction of cholesterol causes a dis-
organization of DRMs allowing more BACE to interact with
APP and to generate Aβ. A strong reduction in cholesterol
inhibits BACE/γ-secretase activities. Despite a direct contact
of BACE/γ-secretase with APP, Aβ generation is blunted. In
cells overexpressing APP, APP can be mislocalized in DRMs
and then cleaved by BACE [230, 233].
12. Conclusion
The pivotal eﬀects of brain cholesterol on diﬀerent cellular
processes in the CNS have become apparent in the last
decades. Most of these studies were performed in patients
with inherited defects of cholesterol biosynthesis and in
transgenic animals with defined mutations. The intriguing
data on the substantial role of cholesterol in the physiology
and pathophysiology of DRMs has been predominantly
obtained in cell culture studies.
While many studies have focused on the cholesterol
metabolism of the whole CNS, late work focused on cell-
specific and evenmicrodomain-specific eﬀects of cholesterol.
Human and animal studies are complicated by diﬀerent
expression of genes involved during development as well
as by cell specific diﬀerences. Another challenge is the role
of the BBB, which also changes during development and
can be regulated under certain pathological conditions. The
sterol flux between CNS cells (namely neurons and oligo-
dendrocytes) is only poorly understood. However, whole
CNS cholesterol production can be very elegantly studied
by analyzing the concentrations of 24(S)-hydroxycholesterol,
the exclusive metabolite of CNS cholesterol. Studies of the
hedgehog signaling cascade in humans were driven by
the SLO syndrome and this disease could be clarified by
studying the genes involved in human patients as well as
in transgenic mice models. Still under discussion are the
options of treatment of CNS diseases by targeting CNS
cholesterol metabolism. Diﬀerences in pharmacology, as well
in the selection of patients, obscure potential beneficial or
detrimental eﬀects and it is currently not recommended to
treat patients with CSI for these indications outside from
clinical trials.
The analysis of CSF lipoproteins revealed some data on
brain cholesterol metabolism. However, no clinical appli-
cable tests have been developed so far which employ CSF
lipoproteins or apos for the clinical diagnosis or for mon-
itoring the eﬀects of certain therapies. Studies of the LDL
receptor family in the CNS showed a very interesting redun-
dancy as well as interaction of these lipoprotein receptors
with a wide array of important signal transduction pathways.
While these receptors are capable of taking up lipoproteins,
this function is only one of many others involved in cell dif-
ferentiation, growth, and function. Isoform-specific eﬀects of
apoE have been the bridge to the processing of APP. A great
number of studies have addressed the rather complicated
molecular processing and the eﬀects of cholesterol (both
in the whole organism as well as in single cells) on this
processing. From current understanding, CNS cholesterol
is an auspicious target for preventing or even treating
Alzheimer’s disease. The full understanding of these process
remains a huge challenge given the increasing number of
older patients, the very complex pharmacokinetics of drugs
targeting the CNS, the long time course of presymptomatic
disease, and many confounding factors identified so far.
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